Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Recruiting · NCT06800612 · Observational (researchers observe without assigning treatment) · Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
View the official record on ClinicalTrials.gov →Interventions studied
Oncologic drug administered for treatment of gynecologic cancerOncologic drugs administered for treatment of breast cancer
What this trial is about
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;
- Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;
- Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.
Exclusion criteria
- no exclusion criteria
Where it is running
1 location listed.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Bologna, Italy